Pcn231 Physician-Reported Comorbidities and Treatment Management in Patients With Non-Metastatic Castration-Resistant Prostate Cancer

Abstract

combination was palbociclib with letrozole (21%). The most prescribed first-line CHT was paclitaxel (40%) and doxorubicin (40%). In second-line therapy, CHT increased to 60%. In those patients who started treatment before 2016, first line therapies were CDK4/6 inhibitors 4%, ET 62% and CHT 61% (39% of those who received two or more treatments). The most frequent first-line CHT was paclitaxel (33%) and the most frequent ET was anastrozole (46%). Sensitivity to hormonotherapy (defined as more than 36 months from the end of ET to beginning of first-line, 20% of all cases) and resistance to previous hormonotherapy (less than 24 months from beginning of ET to beginning of first-line or less than 6 months from beginning of hormone therapy first-line and second-line, 23.0% of cases) were identified as relevant prognostic factors for survival. Conclusions: Treatment patterns for advanced or metastatic breast cancer in Argentina are highly heterogeneous and have experienced substantial changes during the last years. The high CHT use indicates an unmet need for care.